The drug industry may be going through lean times, as new candidates have to clear ever-higher safety hurdles. But this gives scientists who can steer a drug through clinical trials a head start in the job market, says Hannah Hoag.
This is a preview of subscription content, log in via an institution to check access.
Author information
Author notes
Hannah Hoag is a freelance writer based in Montreal, Canada.
- Hannah Hoag
Related links
Related links
Related links in Nature Research
The quiet rise of the clinical contractor
Related external links
Society of Clinical Research Associates
Rights and permissions
About this article
Cite this article
Hoag, H. Trial blazers. Nature 442, 480–481 (2006). https://doi.org/10.1038/nj7101-480a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7101-480a
- Springer Nature Limited
This article is cited by
-
Twenty-first Century ethics of medical research involving human subjects: achievements and challenges
International Urology and Nephrology (2008)
-
Masters of efficiency
Nature Biotechnology (2007)